STOCK TITAN

ZOETIS INC. - ZTS STOCK NEWS

Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.

Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.

The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) announced the acquisition of Basepaws, a petcare genetics company known for its genetic testing and health risk assessments for cats. This strategic move aims to enhance Zoetis’ precision animal health portfolio and R&D capabilities, leveraging Basepaws’ extensive genomic and microbiome databases. Financial details of the acquisition were not disclosed. The partnership is expected to boost innovation in petcare, improving health management and overall quality of care for pets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
-
Rhea-AI Summary

Zoetis (NYSE:ZTS) will participate in the Stifel 2022 Jaws and Paws Conference on June 1, 2022, with Glenn David, Executive Vice President, presenting at 4:10 p.m. ET. Investors can access a live audio webcast of the presentation through the company's investor relations website, where a replay will also be available. Zoetis is a leading animal health company, generating $7.8 billion in revenue in 2021, focused on advancing animal care worldwide. The company operates in over 100 countries with a dedicated workforce of approximately 12,100 employees.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
conferences
Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) has declared a quarterly dividend of $0.325 per share, scheduled for payment on September 1, 2022. Shareholders on record as of July 21, 2022, will receive this dividend. Zoetis remains a leader in animal health, generating $7.8 billion in revenue in 2021 with a robust workforce of approximately 12,100 employees. The company emphasizes its commitment to advancing care for animals across over 100 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
dividends
-
Rhea-AI Summary

Zoetis reported Q1 2022 revenue of $2.0 billion, up 6% year-over-year, and net income of $595 million, reflecting a 6% increase. Adjusted net income reached $625 million, or $1.32 per diluted share, representing a 4% rise. Operationally, revenue grew 9% and adjusted net income 8%, excluding foreign exchange impacts. The company updated its full-year revenue guidance to $8.225 - $8.375 billion primarily due to unfavorable foreign exchange rates. Despite uncertainties from global challenges, Zoetis remains confident in its operational growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
none
-
Rhea-AI Summary

The Zoetis Foundation announced a commitment of $4.9 million to support 20 initiatives across Africa, Brazil, China, Ukraine, and the U.S. The funds will enhance veterinary scholarships, diversity programming, and mental wellness, while also aiding livestock farmers and relief efforts in Ukraine. An initial donation of $150,000 has been made to the Red Cross, with a matching commitment of up to $150,000 for colleague donations. The Foundation aims to improve livelihoods, education, and mental health support for veterinarians and farmers, backed by an overall $35 million commitment through 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
Rhea-AI Summary

Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on May 5, 2022, at 8:30 a.m. (ET) to discuss its first quarter 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the call. Investors can access the live webcast via the Zoetis investor website. Zoetis, the world's leading animal health company, generated $7.8 billion in revenue in 2021 and employs approximately 12,100 people globally. More details and a replay of the call will be available on the website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
conferences earnings
-
Rhea-AI Summary

Zoetis (NYSE:ZTS) will attend the Barclays Global Healthcare Conference on March 17, 2022, where Wetteny Joseph, Executive Vice President and CFO, will present at 9:30 a.m. ET. Interested investors can access a live audio webcast of the presentation at http://investor.zoetis.com/events-presentations. A replay will be available on the Zoetis website afterward. Zoetis, a leading animal health company, generated $7.8 billion in revenue in 2021 and operates in over 100 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.52%
Tags
none
Rhea-AI Summary

Zoetis (NYSE:ZTS) will participate in the Bank of America Securities 2022 Animal Health Summit on February 24, 2022. Wetteny Joseph, CFO, will present at 2:30 p.m. ET, answering questions from analysts. The event will be accessible via a live audio webcast, available at investor.zoetis.com/events-presentations, with a replay provided afterwards. Zoetis is a leader in animal health, generating $7.8 billion in revenue in 2021, with innovations in medicines and diagnostics serving over 100 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
conferences

FAQ

What is the current stock price of ZOETIS (ZTS)?

The current stock price of ZOETIS (ZTS) is $176.42 as of November 18, 2024.

What is the market cap of ZOETIS (ZTS)?

The market cap of ZOETIS (ZTS) is approximately 79.5B.

What does Zoetis Inc. specialize in?

Zoetis Inc. specializes in medicines and vaccinations for pets and livestock, including anti-infectives, vaccines, parasiticides, diagnostics, and other health products.

Is Zoetis Inc. still part of Pfizer?

No, Zoetis Inc. became an independent company after Pfizer spun off its 83% interest.

What percentage of Zoetis' revenue comes from companion animals?

Nearly 65% of Zoetis' revenue comes from companion animal products such as those for dogs, horses, and cats.

Which segment contributes more to Zoetis' U.S. business?

Zoetis' U.S. business is heavily skewed toward companion animals.

How does Zoetis' international business differ from its U.S. business?

Internationally, Zoetis' business is slightly skewed towards production animals, unlike its U.S. business, which focuses more on companion animals.

What recent achievements has Zoetis Inc. accomplished?

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity.

What are Zoetis' current projects?

Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

What is Zoetis' market position in the industry?

Zoetis holds the largest market share in the animal health industry.

Does Zoetis have any strategic partnerships?

Yes, Zoetis has strategic partnerships to expand its market reach and foster innovation.

Where can I find the latest updates on Zoetis Inc.?

You can stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. on StockTitan and other financial news platforms.

ZOETIS INC.

NYSE:ZTS

ZTS Rankings

ZTS Stock Data

79.51B
451.17M
0.2%
96.44%
0.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
PARSIPPANY